Veterinary Stereotactic Radiosurgery System Market

Market Overview The Global Veterinary Stereotactic Radiosurgery (SRS) System Market is projected to grow from USD 3.66 billion in 2025 to USD 6.63 billion by 2031, demonstrating a compound annual growth rate of 10.41%. Veterinary SRS systems are specialized medical devices that deliver high-dose, precisely targeted radiation to treat neoplastic tumors in companion animals while meticulously preserving surrounding healthy tissue. This market's expansion is primarily fueled by the increasing prevalence of cancer within the aging pet population and the growing trend of pet humanization, which drives owners' willingness to invest in advanced veterinary care. Furthermore, rapid advancements in veterinary oncology and the increasing availability of specialized referral centers contribute significantly to the adoption of these systems. As evidence of this commitment, expenditures on veterinary care and product sales in the United States alone reached $39.8 billion in 2024, according to the American Pet Products Association. Market Driver The escalating incidence of cancer and tumors in veterinary patients is a primary force propelling the Global Veterinary Stereotactic Radiosurgery System Market. As companion animals live longer, they become more susceptible to neoplastic conditions such as brain tumors, osteosarcoma, and nasal carcinomas, necessitating precise, non-invasive treatment alternatives. Stereotactic radiosurgery is increasingly preferred for its capacity to deliver ablative radiation doses to these complex targets while preserving healthy tissue, providing a crucial alternative to invasive surgeries. The significant prevalence of such diseases is highlighted by the American Veterinary Medical Association, which reported in February 2025 that approximately one in four dogs will develop cancer during their lifetime, directly fueling the demand for advanced oncology interventions. Simultaneously, the rising trend of pet humanization, coupled with increased healthcare expenditure, is dismantling financial barriers to adopting these sophisticated systems. Pet owners are increasingly treating their animals as integral family members, which translates into a greater willingness to invest in premium medical care, a sentiment further bolstered by the expanding pet insurance sector. This financial capacity is quantitatively supported by data from the North American Pet Health Insurance Association, indicating that the total premium volume in the United States reached $4.7 billion in 2024, marking a 21.4% increase from the previous year. This surge in insured pets and the corresponding financial commitment facilitate the infrastructure for specialized care, exemplified by the growth to 600 board-certified veterinary oncologists in North America by 2024, as noted by Today's Veterinary Practice in June 2025, thereby supporting the wider deployment of radiosurgery platforms. Market Challenge The substantial capital expenditure required for acquiring and installing Veterinary Stereotactic Radiosurgery (SRS) systems presents a significant impediment to the global market's expansion. This financial burden extends beyond the initial purchase price, encompassing the costs of constructing specialized radiation-shielded vaults, retrofitting existing infrastructure, and covering ongoing operational expenses such as maintenance and salaries for highly specialized personnel like veterinary oncologists and medical physicists. Consequently, this economic barrier primarily restricts the accessibility of SRS technology to affluent specialty hospitals and academic institutions, effectively excluding the vast majority of private veterinary practices from adopting these advanced systems. The disparity is evident when considering that, according to the American Veterinary Medical Association's 2025 Report on the Economic State of the Veterinary Profession, the average gross revenue for a U.S. veterinary practice was approximately $1.5 million in 2024. Given that SRS systems often cost substantially more than typical annual earnings, most veterinary facilities lack the financial capacity to implement such technology. This lack of affordability severely limits the total addressable market and prevents the widespread proliferation of SRS capabilities across the broader veterinary sector. Market Trends The veterinary oncology landscape is undergoing a fundamental transformation driven by the increasing adoption of hypofractionated stereotactic treatment protocols, which are redefining clinical standards by replacing prolonged, multi-week radiation courses with high-precision, condensed regimens. This shift is primarily motivated by the critical need to minimize anesthesia-related risks in companion animals, as hypofractionation delivers ablative doses in as few as one to three sessions, contrasting sharply with traditional protracted protocols. The rapid integration of these advanced modalities is clearly reflected in recent clinical caseloads; a retrospective study on veterinary radiation trends, published by the National Institutes of Health in November 2025, reported a remarkable 103.4% increase in the number of patients receiving radiation therapy over a four-year period, underscoring the escalating clinical demand for these sophisticated and efficiency-enhancing treatment options. Concurrently, the proliferation of SRS capabilities in private specialty referral centers is decentralizing advanced cancer care, moving it beyond the exclusive domain of academic teaching hospitals into broader corporate veterinary networks. Large private health groups are making significant investments in state-of-the-art linear accelerators and recruiting board-certified talent, thereby establishing a new echelon of research-driven private practice that rivals the capabilities of university institutions. This structural evolution is quantitatively demonstrated by the academic productivity of these private entities; Mars Veterinary Health's inaugural Science Impact Report in April 2025 revealed that clinicians within its global network authored over 450 peer-reviewed manuscripts in a single year, illustrating how private referral centers have become pivotal drivers of clinical innovation and are expanding the accessibility of radiosurgery services. Key Market Players * Avante Health Solutions LLC * Accuray Inc. * Elekta AB * Varian Medical Systems Inc. * PetCure Oncology LLC * Xstrahl Inc. * CVS Group * Medtronic PLC * Nanovi AS * Merck & Co. Inc. Report Scope In this report, the Global Veterinary Stereotactic Radiosurgery System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Veterinary Stereotactic Radiosurgery System Market, By Product * Gamma Knife * LINAC * Proton Beam Radiation Therapy (PBRT)/ Flash-RT * CyberKnife # Veterinary Stereotactic Radiosurgery System Market, By Application * Brain Tumours * Spinal Tumours * Other Applications # Veterinary Stereotactic Radiosurgery System Market, By End User * Veterinary Hospitals * Veterinary Specialty Clinics * Research & Academic Institutions # Veterinary Stereotactic Radiosurgery System Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Stereotactic Radiosurgery System Market. Available Customizations: Global Veterinary Stereotactic Radiosurgery System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).